Clinical · Molecular biology · Bioinfo & AI
Epigenetic Profiling for Early Detection and Treatment Response Monitoring in Non-Small Cell Lung Cancer: Protocol for a Prospective Translational Biomarker Study
Summary
This prospective translational study aims to identify integrated predictive and prognostic biomarkers (genomic, epigenomic, transcriptomic) from circulating tumor DNA (ctDNA) and tumor tissue for non-small cell lung cancer (NSCLC). The objective is to improve early detection, risk stratification, treatment selection and response prediction, and longitudinal monitoring. The project places a particular emphasis on reducing cancer inequities, especially within Māori communities in New Zealand. Methods include DNA sequencing, cfRRBS DNA methylation profiling, and RNA sequencing, with integrative bioinformatic analyses. Expected findings will support the development of sensitive, accessible, and equitable blood-based biomarkers for NSCLC detection and monitoring.
Critical appraisal
Clinical. This prospective observational translational study has significant long-term clinical impact potential (5+ years) by developing blood-based biomarkers for early detection and treatment response monitoring in NSCLC. By improving detection and risk stratification, it could justify clinical trials for more accessible and equitable screening strategies, particularly for rural and underserved populations, such as Māori communities in New Zealand. The identified biomarkers could be both predictive (for therapeutic selection) and prognostic (for disease monitoring), leading to improved precision oncology.
Molecular biology. The molecular discovery focuses on identifying integrated biomarkers (genomic, epigenomic, transcriptomic) from ctDNA and tumor tissues. The technology employed is state-of-the-art, combining targeted DNA sequencing, genome-scale methylation profiling via cfRRBS (cell-free reduced representation bisulfite sequencing), and RNA sequencing. The use of liquid biopsies (serial peripheral blood samples) is crucial for minimally invasive monitoring. These biomarkers could serve to detect early-stage disease, predict treatment response, and identify resistance mechanisms, paving the way for new clinical tests.
Bioinfo & AI. The study relies on integrative bioinformatic analyses to combine genomic, epigenomic, and transcriptomic data. The goal is to identify molecular signatures associated with different disease stages, treatment response, and therapeutic resistance. The generation of one of the first integrated liquid biopsy datasets for NSCLC in New Zealand is a valuable resource. This data could be used to develop new classification or prediction algorithms, or to improve existing models, potentially for future integration into clinical workflows for patient prioritization or therapeutic decision support.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology